AZT Profitability Analysis: Past Growth, Margins, Return on Capital, Free Cash Flow, and more - Arcticzymes Technologies ASA - Alpha Spread

Arcticzymes Technologies ASA
OSE:AZT

Watchlist Manager
Arcticzymes Technologies ASA Logo
Arcticzymes Technologies ASA
OSE:AZT
Watchlist
Price: 18.4 NOK 3.72% Market Closed
Market Cap: 957.5m NOK
Have any thoughts about
Arcticzymes Technologies ASA?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Arcticzymes Technologies ASA

Revenue
117.7m NOK
Cost of Revenue
-5.3m NOK
Gross Profit
112.4m NOK
Operating Expenses
-100.4m NOK
Operating Income
12.1m NOK
Other Expenses
4.8m NOK
Net Income
16.9m NOK

Margins Comparison
Arcticzymes Technologies ASA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
NO
Arcticzymes Technologies ASA
OSE:AZT
936m NOK
96%
10%
14%
US
Abbvie Inc
NYSE:ABBV
340.3B USD
67%
29%
10%
US
Amgen Inc
NASDAQ:AMGN
181.1B USD
63%
20%
10%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
129.3B USD
87%
31%
32%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.8B USD
86%
41%
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
US
Gilead Sciences Inc
NASDAQ:GILD
104.7B USD
77%
37%
4%
AU
CSL Ltd
ASX:CSL
142.3B AUD
52%
26%
18%
US
Seagen Inc
F:SGT
39.3B EUR
75%
-33%
-33%
US
Palatin Technologies Inc
LSE:0KF3
38.2B USD
97%
-555%
-557%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.7B USD
87%
4%
-3%
Country NO
Market Cap 936m NOK
Gross Margin
96%
Operating Margin
10%
Net Margin
14%
Country US
Market Cap 340.3B USD
Gross Margin
67%
Operating Margin
29%
Net Margin
10%
Country US
Market Cap 181.1B USD
Gross Margin
63%
Operating Margin
20%
Net Margin
10%
Country US
Market Cap 129.3B USD
Gross Margin
87%
Operating Margin
31%
Net Margin
32%
Country US
Market Cap 123.8B USD
Gross Margin
86%
Operating Margin
41%
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Operating Margin
-370%
Net Margin
-392%
Country US
Market Cap 104.7B USD
Gross Margin
77%
Operating Margin
37%
Net Margin
4%
Country AU
Market Cap 142.3B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
18%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 38.2B USD
Gross Margin
97%
Operating Margin
-555%
Net Margin
-557%
Country US
Market Cap 35.7B USD
Gross Margin
87%
Operating Margin
4%
Net Margin
-3%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Arcticzymes Technologies ASA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
NO
Arcticzymes Technologies ASA
OSE:AZT
936m NOK
6%
5%
4%
11%
US
Abbvie Inc
NYSE:ABBV
340.3B USD
54%
4%
16%
12%
US
Amgen Inc
NASDAQ:AMGN
181.1B USD
49%
3%
9%
8%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
129.3B USD
17%
13%
14%
17%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.8B USD
-3%
-2%
25%
-84%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
US
Gilead Sciences Inc
NASDAQ:GILD
104.7B USD
5%
2%
23%
13%
AU
CSL Ltd
ASX:CSL
142.3B AUD
16%
7%
12%
9%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
US
Palatin Technologies Inc
LSE:0KF3
38.2B USD
-588%
-178%
-395%
-5 705%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.7B USD
35%
-2%
4%
9%
Country NO
Market Cap 936m NOK
ROE
6%
ROA
5%
ROCE
4%
ROIC
11%
Country US
Market Cap 340.3B USD
ROE
54%
ROA
4%
ROCE
16%
ROIC
12%
Country US
Market Cap 181.1B USD
ROE
49%
ROA
3%
ROCE
9%
ROIC
8%
Country US
Market Cap 129.3B USD
ROE
17%
ROA
13%
ROCE
14%
ROIC
17%
Country US
Market Cap 123.8B USD
ROE
-3%
ROA
-2%
ROCE
25%
ROIC
-84%
Country US
Market Cap 94.1B EUR
ROE
-877%
ROA
-67%
ROCE
-73%
ROIC
-182%
Country US
Market Cap 104.7B USD
ROE
5%
ROA
2%
ROCE
23%
ROIC
13%
Country AU
Market Cap 142.3B AUD
ROE
16%
ROA
7%
ROCE
12%
ROIC
9%
Country US
Market Cap 39.3B EUR
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 38.2B USD
ROE
-588%
ROA
-178%
ROCE
-395%
ROIC
-5 705%
Country US
Market Cap 35.7B USD
ROE
35%
ROA
-2%
ROCE
4%
ROIC
9%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top